

1
2
3
4
5
6
7
8

9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35



IMDRF International Medical
Device Regulators Forum

PROPOSED DOCUMENT

International Medical Device Regulators Forum

Title: Software as a Medical Device (SaMD): Application of Quality Management System

Authoring Group: IMDRF SaMD Working Group

Date: 26 March, 2015

36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64

Table of Contents

1.0	INTRODUCTION	4
2.0	SCOPE	5
3.0	REFERENCES	6
4.0	DEFINITIONS	7
5.0	SAMD QUALITY MANAGEMENT PRINCIPLES	8
6.0	SAMD GOVERNANCE: LEADERSHIP AND ORGANIZATIONAL SUPPORT	9
6.1	LEADERSHIP AND ACCOUNTABILITY IN THE ORGANIZATION	9
6.2	RESOURCE AND INFRASTRUCTURE MANAGEMENT	9
6.2.1	PEOPLE	10
6.2.2	INFRASTRUCTURE AND WORK ENVIRONMENT	10
7.0	MANAGING SAMD LIFECYCLE PROCESSES	11
7.1	PRODUCT PLANNING	11
7.2	RISK MANAGEMENT: A PATIENT SAFETY FOCUSED PROCESS	12
7.3	DOCUMENT CONTROL AND RECORDS	13
7.4	CONFIGURATION MANAGEMENT AND CONTROL	14
7.5	MEASUREMENT, ANALYSIS AND IMPROVEMENT OF PROCESSES AND PRODUCT	14
7.6	MANAGING OUTSOURCED PROCESSES AND PRODUCTS	15
8.0	SAMD LIFECYCLE ACTIVITIES	17
8.1	REQUIREMENTS	17
8.2	DESIGN	19
8.3	DEVELOPMENT	20
8.4	VERIFICATION AND VALIDATION	21
8.5	DEPLOYMENT	22
8.6	MAINTENANCE	23
8.7	DECOMMISSIONING (RETIREMENT OR END-OF-LIFE ACTIVITY)	24
	APPENDIX A - ISO 13485:2003 REFERENCES	26

65 **Preface**

66

67 The document herein was produced by the International Medical Device Regulators Forum
68 (IMDRF), a voluntary group of medical device regulators from around the world. The document
69 has been subject to consultation throughout its development.

70

71 There are no restrictions on the reproduction, distribution or use of this document; however,
72 incorporation of this document, in part or in whole, into any other document, or its translation
73 into languages other than English, does not convey or represent an endorsement of any kind by
74 the International Medical Device Regulators Forum.

75

76 **1.0 Introduction**

77 The International Medical Device Regulators Forum (IMDRF) seeks to establish a common and
78 converged understanding for software intended for medical purposes and specifically for a subset
79 of such software that is intended to function as a medical device.

80
81 The *IMDRF Software as a Medical Device (SaMD) Working Group (WG)* defines this subset of
82 software as *Software as a Medical Device (SaMD) in the IMDRF SaMD WG N10¹* document; this
83 document is the foundation for developing a common vocabulary and understanding of SaMD for
84 both manufacturers and regulators.

85
86 The SaMD WG has provided a framework to categorize types of SaMD based on impact to public
87 health in the *IMDRF SaMD WG N12* document². This framework establishes a common
88 vocabulary for SaMD, identifies information needed to categorize SaMD, and provides criteria to
89 categorize SaMD based on the combination of the significance of the information provided by the
90 SaMD to the healthcare decision and the healthcare situation or condition where the SaMD is used.

91
92 *The IMDRF SaMD WG N12* document also highlights the use of quality management as a general
93 consideration towards the safety, effectiveness and performance of SaMD and a key to ensuring
94 the predictability and quality of SaMD.

95
96 QMS principles, for many industrial sectors, can be found in the ISO 9000 family of standards. In
97 addition, there are also a wide variety of current industry software development lifecycle
98 methodologies, guidance documents, and standards that address best practices of the many aspects
99 of software engineering quality practices. These principles are the foundation for good practices
100 to maintain and control the quality of products.

101
102 In the medical device industrial sector there is a generally accepted principle that following QMS
103 requirements is one of the controls used to avoid and manage unintentional outcomes from the use
104 of medical devices.

105
106 In practice, specific QMS requirements for medical devices can either be found in regulatory texts
107 such as Good Manufacturing Practices, in guidance documents from regulators, or in the
108 internationally recognized standard ISO 13485.

109
110 Good software engineering is practiced by many software manufacturers to control the quality of
111 their software products. The processes used to accomplish this good engineering practice may
112 readily align with the general principles of QMS requirements.

113
114 This document is a companion document to other IMDRF SaMD WG documents, further enabling
115 convergence in vocabulary, approach and a common thinking for regulators and industry.
116

¹ *IMDRF SaMD WG N10* – “Software as a Medical Device: *Key Definitions*.”

² *IMDRF SaMD WG N12* - “Software as A Medical Device: *Possible Framework for Risk Categorization and Corresponding Considerations*.”

117 The objective of the document is to provide guidance on the application of existing, standardized
118 and generally accepted QMS practices to SaMD.
119

120 This document starts from the perspective of a software development organization (of any size,
121 i.e., could range from a one person enterprise up to a multi-national corporation) that incorporates
122 the activities that are part of good software engineering and quality practices. The document gives
123 an overview of these software quality activities and reinforces medical device quality principles
124 that should be appropriately incorporated for an effective SaMD QMS.

125 2.0 Scope

126 **The purpose of this document is to:**

- 127 • Inform the reader, who is assumed to already be following generally accepted software
128 lifecycle processes³, of SaMD specific practices.
- 129 • Create a bridge for software manufacturers who may not be familiar with medical device
130 QMS and how software engineering and software quality practices may apply for SaMD.
- 131 • Provide guidance for the application of QMS for the governance of organizations
132 responsible for delivering SaMD products and managing the SaMD lifecycle processes
133 (product planning, risk management, document control and records, configuration
134 management and control, measurement, analysis and improvement of processes and
135 products, and managing outsourced processes and product) and SaMD lifecycle activities
136 (requirements, designing, developing, deploying, maintaining and decommissioning).
- 137 • Highlight SaMD lifecycle activities through the lens of patient safety and clinical
138 environment considerations, technology and systems environment considerations that
139 should be addressed to ensure the safety, effectiveness and performance of SaMD.
- 140 • Help manufacturers and regulators attain a common understanding and vocabulary for the
141 application of medical device quality management system requirements to SaMD.
- 142 • Complement the IMDRF SaMD framework for risk categorization and corresponding
143 considerations [[http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-140918-
144 samd-framework-risk-categorization-141013.pdf](http://www.imdrf.org/docs/imdrf/final/technical/imdrf-tech-140918-samd-framework-risk-categorization-141013.pdf)].

145 **This document is intended for the following audience:**

- 146 • Groups and/or individuals who are or want to become developers of SaMD
- 147 • Software development organizations (large or small) that apply good software quality and
148 engineering practices and that may not necessarily be familiar with medical device QMS
149 requirements.
- 150 • Organizations (divisions/departments) working within established medical device quality
151 systems that intend to communicate the linkage between medical device quality system
152 practice and SaMD development practices.

153 **Document organization and content:**

- 154 • Terminology used is intended to be familiar to the software industry and illustrates how
155 typical software-engineering activities (e.g., determining requirements) translate to

³ These lifecycle processes are intended to include commonly referred lifecycle processes such as software development lifecycle processes (SDLC), software product lifecycle processes (SPLC) and Software System lifecycle processes (SSLIC).

156 equivalent activities in a medical device quality management system (e.g., identifying
157 'design inputs') used in the management, design, development, implementation,
158 monitoring and support of SaMD.

- 159 • Sections are organized based on processes and activities commonly found in software
160 engineering lifecycle approaches as well as the leadership and management of the
161 organization as a whole.
- 162 • SaMD lifecycle processes and lifecycle activities include considerations that are necessary
163 to address patient safety and clinical environment as well as the technology and systems
164 environment for SaMD.
- 165 • Throughout this document, examples using two fictitious companies – ACME (a large
166 organization) and J&M (a small start-up) — are provided to highlight some of the key
167 points being made.
- 168 • ISO13485:2003 is used as the reference material as it is the most widely used QMS
169 standard within the medical device industry.

170 **Field of application:**

- 171 • The guidance for the application of QMS provided in this document applies to SaMD as
172 defined in the related document, *IMDRF SaMD WG N10 / Software as a Medical Device:
173 Key Definitions* and does not address other types of software.
- 174 • This document focuses on SaMD irrespective of technology and/or the platform (e.g.,
175 mobile app, cloud, server, etc.).

176 **This document is not intended to:**

- 177 • Provide guidance on good software engineering practice.
- 178 • Rewrite or repeat QMS principles that are articulated in medical device regulations or
179 standards.
- 180 • Address software that drives or controls a hardware medical device.

181 **Relationship to regulatory requirements and to technical standards:**

- 182 • The document does not replace or create new QMS, standards, software engineering
183 practices, or regulations; rather, it highlights common practices and terminology used by
184 successful software organizations.
- 185 • This document is not a tutorial on risk management practices for software; rather it
186 highlights risk management principles throughout the software lifecycle processes and
187 activities that are critical to the safety, effectiveness and performance of SaMD.
- 188 • The activities highlighted in this document are not meant to replace or conflict with the
189 content and/or development of technical or process standards related to software risk
190 management activities or software development practices.

191 **3.0 References**

- 192 • IMDRF SaMD WG N10 / Software as a Medical Device: Key Definitions
- 193 • IMDRF SaMD WG N12 / Software as a Medical Device: Possible Framework for Risk
194 Categorization and Corresponding Considerations
- 195 • ISO 13485:2003 – Quality management system – Requirements for regulatory purposes
- 196 • ISO 12207:2008 – Systems and software engineering – Software lifecycle processes

197 **4.0 Definitions**

198 This document does not introduce any new definitions but rather relies on the following:

- 199 • Definition of SaMD as identified in IMDRF SaMD WG N10 / Software as a Medical
200 Device: Key Definitions and does not address other types of software.
- 201 • Terms typically used in standards and regulation as they relate to QMS for medical devices
- 202 • Terms and vocabulary used in the software quality practices and software engineering.

203 **5.0 SaMD Quality Management Principles**

204 Medical device QMS principles allow for scaling depending on the type of medical device, risk of
 205 the product to patients, size of the organization, technology or automation used to manufacture,
 206 and other factors that are determined by the manufacturer to control quality and maintain the safe
 207 and effective performance of the medical device.

208
 209 The manufacturing of SaMD, which is a software only product, is primarily based on the
 210 development lifecycle activities often supported by the use of automated software development
 211 tools (e.g. build automation, use of a source code management tool, etc.). These automated
 212 processes may in some cases replace discrete or deliberate activities (e.g., transfer of design to
 213 production) typically found in the manufacturing of hardware products. However, the principles
 214 in a QMS that provide structure and support to the lifecycle processes and activities are still
 215 applicable and important to control the quality of SaMD.

216
 217 An effective QMS for SaMD should include all of the following principles:

- 218 • A governance structure that provides leadership, accountability and an organization with
 219 adequate resources that assures the safety, effectiveness and performance of SaMD (outer
 220 circle in figure 1);
- 221 • A scalable set of quality processes that apply commonly across SaMD lifecycle processes
 222 (middle circle in figure 1); and
- 223 • A set of key lifecycle activities that is scalable for the type of SaMD, the size of the
 224 organization and takes into account important elements required for assuring the safety,
 225 effectiveness and performance of SaMD (innermost circle in figure 1).
- 226 • The governance represented by leadership and organizational support is the foundation that
 227 supports the management of SaMD lifecycle processes which in-turn supports the SaMD
 228 lifecycle activities.



229
 230 **Figure 1: SaMD Quality Management Principles: Relationship Between Governance, Processes and Activities**

231 *The following references in ISO 13485:2003 are applicable to this section: 4 and 5*

232 **6.0 SaMD Governance: Leadership and Organizational Support**

233 **6.1 Leadership and accountability in the organization**

234 Management of the organization is providing the
 235 leadership and an overall governance structure for all
 236 activities related to the lifecycle activities of SaMD
 237 including defining responsibility, authority, and
 238 communication of quality objectives for all relevant
 239 areas that have an impact on the quality of SaMD. The
 240 organization’s leadership is also responsible for implementing the QMS, which can include
 241 developing a quality policy, quality objectives, and project-specific plans that are customer
 242 focused. The governance structure should provide support for creating and establishing appropriate
 243 processes that are important for maintaining the quality objectives and policies⁴. In addition the
 244 governance should include an overall process for systematically verifying the effectiveness of the
 245 established quality management system (periodic QMS internal audit). Management review of the
 246 results of the QMS verification is a tool to ensure that the established QMS is suitable, adequate,
 247 and effective and makes any necessary adjustments as a result.



248
 249 *Example: In the case of ACME, a product development project is governed at strategic points*
 250 *during a phase-gate process by a cross-functional set of management leaders. As ACME enters*
 251 *the SaMD market, an additional member may need to be added or an existing member may need*
 252 *to take on the additional role of ensuring adherence to patient safety and QMS requirements at all*
 253 *points throughout the product development and deployment lifecycle.*

254
 255 *In the case of J&M, each of the principals has been equally responsible and accountable for*
 256 *multiple roles/tasks. As they enter the SaMD market, each will also be responsible for adherence*
 257 *to applicable QMS requirements, with perhaps a designated leader or “enforcer” of applicable*
 258 *QMS requirements.*

259
 260 *The following references in ISO 13485:2003 are applicable to this section: 5 and 8.2.2*

261 **6.2 Resource and Infrastructure Management**

262 The purpose of resource management is to provide the appropriate level of resources (including
 263 people, tools, environment, etc.), as needed for ensuring the effectiveness of the SaMD lifecycle
 264 processes and activities in meeting regulatory and customer requirements.

265
 266 *Example: In ACME, this may be easier to accomplish, as resources and funding for such a*
 267 *management responsibility may exist. However, in the case of J&M, it is something that they will*
 268 *likely research and implement with existing resources.*

269
 270 *The following references in ISO 13485:2003 are applicable to this section: 6*

⁴ These processes should be tailored specifically towards the needs of the organizations and the level of formal documented processes, objectives and policies should be adjusted appropriately for the type, size and distributed nature of the organization.

271 **6.2.1 People**

272 It is important to ensure that people who are assigned to SaMD projects should be competent to
273 perform their jobs. For SaMD this may include software engineers, engineering managers, testers,
274 etc., who are competent in the technology and software development practices.

275
276 *Example: In the case of ACME, training and education programs may be well-established and*
277 *adding specific training for SaMD or hiring trained individuals might be easily accomplished. For*
278 *J&M, a well-established training program may not exist, however ensuring persons with the right*
279 *training and educational background to match the SaMD specific tasks required of them are*
280 *available accomplishes the goal.*

281
282 *The following references in ISO 13485:2003 are applicable to this section: 6.1 and 6.2*

283 **6.2.2 Infrastructure and Work Environment**

284 Infrastructure: equipment, information, communication networks, tools, the physical facility, etc.,
285 should be made available throughout SaMD lifecycle processes. Such infrastructure is used to
286 support the development, production, and maintenance for SaMD and as such needs to be provided
287 and maintained. For SaMD this may entail identifying and providing the software development
288 and testing environment that simulates the specific technology and configuration and customer
289 needs. These tools should support managing various software configurations during the lifecycle
290 processes, e.g., version management for source code during development, etc.


291
292 As the work environment becomes more virtual, the reliability and dependability of the collective
293 infrastructure environment is an important consideration (e.g. dependence on 3rd party networks
294 and equipment).

295
296 *Example: In the case of ACME, existing computer networks and secure building access might be*
297 *leveraged directly for SaMD development. However, J&M's development environment (which*
298 *could have been a single server that was managed virtually and more informally) may need to be*
299 *separated into multiple environments (e.g., development, QA, staging, demo, production). Doing*
300 *so would help ensure code integrity, security, reliability, continuity of service to patients and*
301 *security across these different infrastructure environments in the wake of day-to-day development,*
302 *upgrades, scheduled and unscheduled maintenance, patches, etc.*

303
304 *The following references in ISO 13485:2003 are applicable to this section: 6.3 and 6.4*
305
306

307 **7.0 Managing SaMD Lifecycle Processes**

308 An organization's QMS must be built and managed
 309 around processes that support the lifecycle activities of
 310 SaMD. This section addresses important processes that
 311 cut across the SaMD lifecycle activities regardless of the
 312 intended use of the SaMD (i.e., significance of the
 313 information provided by the SaMD to the healthcare decision and the state of the healthcare
 314 situation or condition). There are many available methods to conduct SaMD Lifecycle processes,
 315 these processes are typically scaled to address the complexity and size of the SaMD product and
 316 project (for e.g. during new product introduction or for an upgrade) that needs to be created.



317
 318 The sections below: product planning; risk management: a patient safety focused process;
 319 document control and records; configuration management and control; measurement, analysis and
 320 improvement of processes and product; and managing outsourced processes and product are
 321 common processes that are required to be considered throughout the SaMD lifecycle activities
 322 regardless of specific approach/method used by the organization. Appropriate implementation of
 323 clearly structured and consistently repeatable decision-making processes by SaMD organizations
 324 can provide confidence that efforts to minimize patient safety risk and promote patient safety have
 325 been considered.

326 **7.1 Product Planning**

327 The objective of planning is to provide a roadmap to be followed during the product development
 328 lifecycle. This comes from the quality principle that better results are achieved by following a
 329 plan-do-check-act (also known as the PDCA cycle) approach. Product planning includes the
 330 definition of phases, activities, responsibilities and resources needed for developing the SaMD. It
 331 is important to understand that planning is not static — it needs to be updated when new
 332 information is gathered or milestones are reached.

333
 334 In *IMDRF SaMD WG N12 / Software as a Medical Device: Possible Framework for Risk*
 335 *Categorization and Corresponding Considerations* identifies that for SaMD, a thorough
 336 understanding of the socio-technical environment (clinical perspective) and the technology and
 337 system environment (software perspective) is important in planning as inadequate considerations
 338 could lead to incorrect, inaccurate, and/or delayed diagnoses and treatments.⁵

339
 340 The implementation of SaMD lifecycle activities should adequately be informed and tailored for
 341 the type of SaMD as identified in *IMDRF SaMD WG N12*.

342
 343 *Example: The larger Acme Company may have existing planning staff with software based*
 344 *planning tools while the smaller J&M may rely upon other methods. In either case, the plan should*
 345 *be designed to identify tasks to be completed, goals to be achieved, documentation necessary to*
 346 *support the plan and the project, along with appropriate resource and time allocation to achieve*
 347 *the desired results. For both J&M and ACME, this planning phase can employ a model that takes*

⁵ IMDRF SaMD WG N12 / Software as a Medical Device: Possible Framework for Risk Categorization and Corresponding Considerations - Section 9.1 Socio-technical environment considerations and Section 9.2 Technology and system environment considerations.

348 *a deliberate approach to the assignment of resources and reviewed periodically to ensure progress*
349 *against stated project objectives.*

350
351 *The following references in ISO 13485:2003 are applicable to this section: 5.4, 7.1 and 7.3.1*

352 7.2 Risk Management: A Patient Safety focused process

353 *IMDRF SaMD WG N12* provides a possible framework to categorize types of SaMD based on
354 impact to public health. Using the foundational categorization in *IMDRF SaMD WG N12*, the
355 safety, effectiveness and performance of SaMD, can be assured by appropriate risk management.
356 This risk management process should not be considered singularly in any one process or activity;
357 rather it should be integrated across the entire lifecycle of SaMD.

358
359 Just as the general software development industry continuously monitors and manages schedules
360 and budget risks of a software project, a SaMD organization should in addition, and more
361 importantly, monitor and manage risks to patients and users across all lifecycle activities.

362
363 For SaMD, lifecycle process and product risk should be informed by the intended purpose, the
364 reasonable foreseeable use, and the understood and defined socio-technical environment of use of
365 the SaMD. Some general considerations associated with SaMD patient safety risk which should
366 be considered throughout the lifecycle activities include the ease with which a SaMD may be
367 updated, duplicated and distributed due to its non-physical nature, and where these updates, made
368 available by the SaMD organization, may be installed by others,

369
370 Risk management in the context of this document addresses taking a risk-based approach to patient
371 safety. Specifically, related to QMS, some points that should be considered include:

- 372 • The need to identify and act on identified risks
- 373 • Actions to address risks and opportunities
- 374 • The prevention or reduction of undesired results

375
376 For example, it is helpful to chart sources of risk along multiple dimensions, such as:

- 377 • User-based risks: Is the SaMD product appropriate for all intended users? For instance,
378 are there risks posed by visual acuity for an elderly user, or for patients with peripheral
379 neuropathy?
 - 380 • Application-based risks: Should a SaMD application be available on any device, or should
381 it be restricted to certain devices in such a way that it could help to mitigate user risk?
 - 382 • Device-based risks: Is a device with a smaller screen such as a smartphone adequate for
383 the intended application, can a smaller screen display a large set of information without
384 losing the information or making it cumbersome to the users in a way that could affect
385 patient safety.
 - 386 • Environment-based risks: Is continuity of use (and therefore, safety) of the SaMD product
387 compromised when there are environmental disruptions (e.g., what happens with use
388 interruptions, background noise, loss of network connectivity during use, etc.)
 - 389 • Security-based risks: Analysis should include evaluating the security threats to SaMD
390 product software code during manufacturing, maintenance and in-service use. Analysis can
391 also include intrusion detection, penetration testing, vulnerability scanning and data
392 integrity testing to minimize system and patient risks.
-

393
394 Software risk assessment requires a balanced evaluation of both safety and security. Security risks
395 may affect the confidentiality, integrity, and availability of data handled by the SaMD. When
396 considering mitigations to protect device security, the manufacturer should ensure that security
397 risk controls do not take precedence over safety considerations.

398
399 *Example: For both ACME and J&M, it is useful to create a set of “use-case scenarios”, and*
400 *assess risks in each of the above dimensions by assessing both likelihood of a risk occurring and*
401 *the associated severity or impact of the risk to the patient. For example, if a patient is entering*
402 *their weight to track on a smart phone, the likelihood of a “typing error” may be high, but its*
403 *impact low, as it’s merely a weight log. However, if a SaMD product is requiring a patient to*
404 *enter their weight in order to provide them some form of feedback on medication, or diet, then the*
405 *impact of the error may be higher, and methods may need to be employed to ensure that the correct*
406 *value has been entered.*

407
408 *The following references in ISO 13485:2003 are applicable to this section: 7.1*

409 7.3 Document Control and Records

410 Records are used to provide evidence of results achieved or activities performed or not adequately
411 performed as a part of the QMS or SaMD lifecycle processes as well as justifications for QMS
412 activities or SaMD lifecycle processes not performed. Records can be in paper or electronic form.

413
414 For SaMD lifecycle processes, document control and records management makes it easier for the
415 users of those documents and records, both within and outside the organization (e.g., outsourced
416 contractors, customers, etc.) to share and collaborate in the many activities related to the SaMD
417 lifecycle process activities, e.g., code development, resolving issues, decommissioning, etc.
418 Document control and records management also serves to help communicate and preserve the
419 rationale for why certain decisions related to SaMD, e.g., related to patient safety or risk
420 management, were made.

421
422 Records generated to demonstrate QMS conformity should be appropriately identified, stored,
423 protected, and retained for an established period of time. The following key processes should be
424 integral to managing and maintaining appropriate documentation in the QMS system:

- 425 - Reviewing and approving documents before use
- 426 - Ensuring current version of applicable documents are available at points of use, (i.e.
427 preventing use of obsolete documents).
- 428 - Retaining obsolete documentation for an established period.
- 429 - Controlling documents against unauthorized or unintended changes.
- 430 - Maintaining and updating documents across all SaMD lifecycle activities.

431
432 *Example: In the cases of ACME and J&M, it is important to align document complexity with*
433 *organizational maturity. Documentation does not mean bureaucracy. Rather, it is the basis to*
434 *drive traceability, repeatability, scalability and reliability in SaMD projects. While ACME may*
435 *have established documentation processes and techniques that can be used, J&M need not adopt*
436 *the same processes and techniques that might be necessary for a larger company. Instead, J&M*
437 *may be able to standardize their existing documentation methods using formally controlled*

438 *(reviewed and approved) examples of their current documentation, which may be simpler in nature.*
439 *Either of these options is acceptable and serves to illustrate the flexibility of applying these*
440 *concepts and processes.*

441
442 *The following references in ISO 13485:2003 are applicable to this section: 4.2*

443 7.4 Configuration Management and Control

444 Control of configurable items (including source code, releases, documents, etc..) is important to
445 maintain the integrity and traceability of the configuration throughout the SaMD lifecycle.

446
447 A systematic documentation of the SaMD and its supporting design and development is necessary
448 to identify its constituent parts, to provide a history of changes made to it and to enable
449 recovery/recreation of past versions of the software, i.e., traceability of the SaMD.

450
451 For SaMD, configuration is also an important consideration to enable the correct installation and
452 integration of the SaMD into the clinical environment. This information enables users to decide
453 whether or not the SaMD can be used with for example, available hardware, competencies,
454 networks, or whether it is necessary to establish different routines and training or obtain necessary
455 hardware.

456
457 In the management of SaMD configuration, software tools are generally used to manage source
458 code, releases, documents, deployment, maintenance, etc. In SaMD, the notion of configuration
459 management and its complexity is amplified by the heterogeneity of the environment in which the
460 SaMD will operate and using the right tools and techniques is important.

461
462 *Example: For both ACME and J&M, patients can access the SaMD products through multiple*
463 *devices (e.g., Smartphone, PC, Tablet, etc.) each of which may require specific configurations and*
464 *optimization of user experiences. This requirement enforces the importance of a robust and*
465 *documented configuration management process, which might not be well-established at a smaller*
466 *or newer company such as J&M.*

467
468 *The following references in ISO 13485:2003 are applicable to this section: 4.2.3, 4.2.4, 7.3.7,*
469 *7.5.1, and 7.5.3*

470 7.5 Measurement, Analysis and Improvement of Processes and Product

471 Measurement of quality characteristics of software products and processes is used to manage and
472 improve product realization. An effective measurement process of key factors, often associated
473 with issues related to risk, can help identify the capabilities needed to deliver safe and effective
474 SaMD. Opportunities to monitor, measure and analyze for improvement exist before, during and
475 after a process is completed or the SaMD released and should objectively demonstrate the quality
476 of the SaMD. These processes can include identifying, collecting, analyzing and reporting on
477 critical quality characteristics of products developed.

478
479 For SaMD, monitoring, through objective measurement, to demonstrate that processes are being
480 followed does not itself guarantee good software, just as monitoring software quality alone does
481 not guarantee a sufficient process. The effectiveness of the SaMD lifecycle processes and of the

482 SaMD itself should be evaluated based on predetermined procedures (e.g. leading and lagging
483 safety indicators) to collect and analyze appropriate data. The analyses of this data (including, for
484 example, adverse event reporting, problem reports, bug reports, customer complaints,
485 nonconformity to product requirements, service reports, characteristics and trends of processes and
486 products) are used to evaluate the quality of the SaMD, and the quality of the SaMD lifecycle
487 processes and activities and where/if improvement of these processes and activities can be made.
488

489 For SaMD, when a process is not followed correctly, or the SaMD does not meet the quality
490 requirements (i.e., a nonconforming process or product), corrections are required. Nonconforming
491 SaMD should be isolated to prevent unintended use or delivery. The cause of the problem (i.e.,
492 SaMD nonconformity) should be analyzed and actions taken to correct or eliminate the problem
493 (i.e., corrective action), and to prevent the same or similar problems occurring in the future. In
494 some cases a potential nonconformity may be identified, and actions such as safeguards and
495 process changes can be taken to prevent nonconformities from occurring (i.e., Preventive Action).
496 Actions taken to address the cause of SaMD nonconformities as well as action taken to eliminate
497 potential SaMD nonconformities should be evaluated for effectiveness.
498

499 Lessons learned from the analysis of past projects, including the results from audits of the SaMD
500 lifecycle processes (periodic internal and external) can be used to improve the safety, effectiveness
501 and performance of SaMD lifecycle processes and activities. The manufacturer should also have
502 processes in place for the collection of active and passive post-deployment surveillance
503 information in order to make appropriate decisions relating to future releases.
504

505 *Example: Preventive actions are often identified during the risk assessment phases of the product*
506 *realization process. For example, potential risks might be associated with the use of OTS software*
507 *that exchanges measurement data with the SaMD. Preventive actions to mitigate unacceptable*
508 *risks from invalid data might be to include fuzz testing of the OTS software during acceptance,*
509 *and to perform comprehensive error checking of the incoming data during program execution.*
510

511 *The following references in ISO 13485:2003 are applicable to this section: 7.2.3, 8.1, 8.2, 8.3, 8.4,*
512 *and 8.5*

513 7.6 Managing Outsourced Processes and Products

514 The organization must establish controls that allow it to ensure both, the quality of any outsourced
515 process or product, i.e., any outside software or service supplied to the SaMD organization or
516 integrated into the SaMD (software, contractor, consultant, etc.), and that required process steps
517 within the SaMD lifecycle are being performed. Such controls can include review of deliverables,
518 intermediate result inspection, or audits of the contractor or supplier.
519

520 In the case of SaMD, managing outsourced processes and product can include the development of
521 portions of SaMD, the use of 3rd party software or integrating commercial off the shelf (OTS)
522 libraries.
523

524 Outsourcing is more effective, when contractors, consultants, or suppliers understand the product
525 and its application domain. For SaMD, where a software module may be outsourced to software
526 contractor(s), it is important to clearly communicate the roles and responsibilities of the software

IMDRF/SaMD WG (PD1)/N23R3

527 contractor(s) and conditions for the outsourced product through the use of contractual terms to
528 manage or mitigate patient safety risk.

529
530 If and when some of the SaMD product is outsourced, i.e., when making use of 3rd party software
531 or integrating OTS software, the SaMD organization is responsible for the safety, effectiveness
532 and performance of the SaMD throughout its lifecycle. For example, when a SaMD incorporates
533 an OTS database (e.g., SQL, etc.), the SaMD organization should understand the capabilities and
534 limitations of the outsourced product throughout the SaMD lifecycle.


535
536 *Example: ACME and J&M may have historically used open-source code or other OTS code as*
537 *part of their product development. In the development of SaMD, it is critical for both ACME and*
538 *J&M, to properly verify and validate the integration of open source code or OTS code. It is also*
539 *critical to formally evaluate, document, and periodically audit suppliers to ensure compliance with*
540 *QMS requirements.*

541
542 *The following references in ISO 13485:2003 are applicable to this section: 7.4, 7.4.1, 7.4.2 and*
543 *8.5.1.*

544

545 **8.0 SaMD Lifecycle Activities**

546 This section identifies key lifecycle activities that should
 547 be identified in the methodologies used in an
 548 organization that manufactures SaMD. The following
 549 are important perspectives that should be considered for
 550 each of the activities in this section.



- 551 • SaMD lifecycle processes in Section 7.0 (product planning; risk management: a patient
 552 safety focused approach; document control and records; configuration management and
 553 control; measurement, analysis and improvement of processes and product; managing
 554 outsourced processes and products) should be applied throughout the lifecycle activities.
- 555 • This section highlights those activities commonly found in software engineering lifecycle
 556 approaches (process, activities, tasks, etc.) that are important for an effective SaMD QMS.
- 557 • The activities presented in this section should be included irrespective of methodology used.
 558 The presentation of the material does not imply executing the activities in a serial fashion
 559 or as discrete phases in the SaMD project (e.g., waterfall process method, etc.); rather these
 560 activities should be looked upon as elements to be addressed in any continuous
 561 development methodology (e.g., Agile, Extreme, etc.).
 562

563 *The following references in ISO 13485:2003 are applicable to this section: 7*

564 **8.1 Requirements**

565 Developing appropriate requirements helps to ensure that SaMD will satisfy the needs across the
 566 socio-technical environment including users and patients. These clinical needs should be clearly
 567 articulated and the requirements captured in line with the intended use of SaMD as characterized
 568 by the "state of the healthcare situation or condition" and the "significance of information
 569 provided by SaMD to the healthcare decision" and the resulting impact to public health as
 570 identified in *IMDRF SaMD WG N12*.
 571

572 This is a customer-driven process that requires clear, and often repeated, customer interface to
 573 understand the user needs. These user needs are then translated into requirements. Well-
 574 documented requirements can then inform the testing activities later in the design cycle. There
 575 are other sources of requirements that can include, regulatory or non-customer specified
 576 performance requirements.
 577

578 ***Patient Safety and Clinical Environment Considerations***

- 579 • SaMD are used in clinical environments and therefore, in addition to functional
 580 requirements, there are requirements that include considerations of user, patient and third
 581 party safety. Therefore, some requirements originate from the risk management process
 582 that evaluates risks to patients and risk to users and may identify mitigations that become
 583 part of requirements.

- 584
- 585
- 586
- 587
- 588
- 589
- 590
- 591
- 592
- Further considerations need to be given to the integrity of data used in the SaMD which may result in specific requirements to ensure that data is secure and to mitigate against the loss or corruption of sensitive data.⁶
 - Requirements for SaMD often need to include additional and specific requirements for performing upgrades that consider potential impact to peripheral components of the system as well as appropriate notification and coordination with customers.⁷
 - For SaMD, there may be a need to identify and use communication channels that are different from the historical ones (usually involving electronic communication).

593 ***Technology and Systems Environment Considerations***

- 594
- 595
- 596
- 597
- 598
- 599
- 600
- SaMD runs on an underlying platform and operating system, often from a third party. These should be considered as part of the requirements because they can be significant sources of risk.
 - Requirements may also need to define non-software aspects of a system.
 - Requirements should be captured in concert with stakeholders in the process and should not be captured solely by software or system engineers.

601 Note: Requirements may change as the developer better understands how the SaMD functions in
602 the clinical environment and as a customer uses it. Therefore, it is important to apply good
603 human factors engineering principles to the development and testing the software to ensure that
604 the requirements were appropriately translated into design inputs.

605

606 *Example: Whether you are ACME or J&M, requirements serve the purpose of clearly defining*
607 *what is to be developed in the SaMD product. Requirements also enable traceability of the test*
608 *outcomes to each requirement. That being said, there are different acceptable ways to capture*
609 *requirements. In the case of ACME, it is more likely that the existing process and documentation*
610 *would suffice, and that requirements would be captured by a cross-functional product team to*
611 *ensure a “360-degree” view of requirements for the SaMD features. In the case of J&M, screen*
612 *shots, sketches and rapid prototypes that clearly communicate product requirements may also be*
613 *acceptable. These may also be sufficient to meet the testing traceability needs of the SaMD QMS*
614 *requirements provided the necessary control of these requirement artifacts is established and*
615 *maintained and a sense of cross functionality is achieved, either through internal resource*
616 *collaboration or often, through dialog or workshops with prospective customers and users of the*
617 *envisaged SaMD product.*

618

619 *The following references in ISO 13485:2003 are applicable to this section: 7.2.1, 7.2.2, 4.2 and*
620 *7.1d*

⁶ IMDRF SaMD WG N12 / Software as a Medical Device: Possible Framework for Risk Categorization and Corresponding Considerations - Section 9.3 Information security with respect to safety considerations

⁷ IMDRF SaMD WG N12 / Software as a Medical Device: Possible Framework for Risk Categorization and Corresponding Considerations - Section 8.2 Changes

621 8.2 Design

622 The purpose of the SaMD design activity is to define the architecture, components, and
623 interfaces of the software system, based on user requirements and any other performance
624 requirements in line with the intended use of the SaMD and the clinical / technological
625 environment it will operate in. The requirements are analyzed in order to produce a description
626 of the software's internal structure that will serve as the basis for its implementation. When
627 complete, the SaMD design activity will describe the software architecture, i.e., how the software
628 is decomposed and organized into its components, including considerations for safety critical
629 elements, the interfaces between those components (and any external elements) and a detailed
630 description of each component.

631
632 One of the key aspects of the design process is to arrive at a clear and concise design solution
633 that is an effective, well described (e.g., captured in software requirements specifications),
634 logical architecture that best meets the user needs and enables other lifecycle activities such as
635 verification, validation, safe deployment and maintenance of the SaMD.
636

637 *Patient Safety and Clinical Environment Considerations*

- 638 • Where a SaMD will be used -- in the home, at the hospital bedside, in a physician's office
639 or clinic -- the users, (e.g. patients, providers and anyone else who can interact or use the
640 information from the SaMD) must be considered in the design activities.
- 641 • Clinical risk already identified must be an input to the design phase.
642

643 *Technology and Systems Environment Considerations*

- 644 • There are aspects of architectural design that may be driven by the safety critical nature
645 of SaMD and by the risk mitigation solutions, which may include segregation of specific
646 functions into particular modules that are isolated from other areas/modules of the
647 software.
- 648 • SaMD design should be robust enough to survive unanticipated upgrades of the
649 underlying platform.
650

651 *Example: It may be helpful, in an organization of any size, to modularly design SaMD software*
652 *to allow separability (and hence, scalability) of the data, logic and user-interface (UI) layers.*
653 *This way, as the SaMD product evolves with either new data fields, new logic or new UI*
654 *enhancements, it's easier to ensure traceability to SaMD requirements and enable adequate*
655 *regression testing to make sure "nothing is broken" as a result of the additions.*
656 *The following references in ISO 13485:2003 are applicable to this section: 7.3, 7.3.2, 7.3.3, 7.3.4*
657 *and 7.3.7*
658

659 **8.3 Development**

660 The development activity transforms the requirements, architecture, design (including interface
 661 definition), recognized coding practices (secure) and architecture patterns into software items and
 662 the integration of those software items into a SaMD. The result is a software item/system/product
 663 that satisfies specified requirements, architecture and design. Good development practice
 664 incorporates appropriate review processes, (e.g. code review, peer review, creator self-review, etc.)
 665 and follows a defined implementation strategy (e.g. build new, acquire new, re-use of existing
 666 elements). Use of appropriately qualified automated tools and supporting infrastructure is
 667 important for managing configuration and having traceability to other lifecycle activities.
 668

669 ***Patient Safety and Clinical Environment Considerations***

- 670 • The implementation of clinical algorithms adopted in the code must be clear, in order to
 671 avoid misuse or unintentional use.
- 672 • The implementation of proper access controls and audit trail mechanisms should be
 673 balanced with the usability of SaMD as intended.
 674

675 ***Technology and Systems Environment Considerations***

- 676 • Development activity should leverage the inherent nature of SaMD that allows for efficient
 677 methods to understand the user’s environment and prevent and manage failures.
- 678 • Attention to detail is critical in areas of underlying implementation of the algorithm - a
 679 simple data overwrite can potentially lead to an adverse patient safety impact. Some
 680 examples of these critical areas include: memory usage and allocation, dependency on
 681 communication, speed of operation, and prioritization of tasking, display management and
 682 user input capability.
- 683 • Many SaMD deal with data entry, and the methods through which data is validated and the
 684 impact to the downstream data consumer is an important SaMD consideration.
- 685 • As SaMD runs on an underlying platform, rigorous and strict adherence to development
 686 guidance as set forth by the platform developer should be followed to ensure backward
 687 compatibility.
 688

689 *Example: Software development typically employs a “bug severity” scale (e.g., Severity 1=*
 690 *cosmetic error, Severity 2=functional error, Severity 3=failure, etc.). In SaMD, for both ACME*
 691 *and J&M severity should also be based on patient safety risk related to the healthcare situation or*
 692 *condition⁸ (e.g., non-serious, serious, or critical). In other words, there may be bugs that do not*
 693 *cause failures, but that can lead to higher patient safety risk; these instances merit the same*
 694 *attention as a failure. This practice is applicable regardless of the scale of the enterprise.*
 695

696 *The following references in ISO 13485:2003 are applicable to this section: 7.3, 7.3.2, 7.3.3, 7.3.4*
 697 *and 7.3.7*

⁸ IMDRF SaMD WG N12 / Software as a Medical Device: Possible Framework for Risk Categorization and Corresponding Considerations - Section 5.2 Healthcare Situation or Condition

698 **8.4 Verification and Validation**

699 The verification and validation (V&V) activities should be targeted towards the safety-critical
 700 nature of SaMD. Typically verification (providing assurance that the design and development
 701 activity conforms to the requirements) and validation (providing reasonable confidence the
 702 software meets its operational requirements) activities ensure that all elements (including user
 703 needs) from the SaMD design and development – including any changes made during
 704 maintenance/upgrades – have been implemented correctly and that objective evidence of this
 705 implementation is recorded. As SaMD runs on an underlying platform, a defined set of
 706 verification and validation activities must focus on that interface to the operating system,
 707 outsourced components, and other dependencies.
 708

709 ***Patient Safety and Clinical Environment Considerations***

- 710 • These V&V activities should include scenarios that cover the clinical user/use environment
 711 (usability, instructions for use, etc.). This can be accomplished, for example, through
 712 structured human factors testing on a subset of patients.
- 713 • These activities should confirm that software safety elements work properly (i.e., patient
 714 safety / clinical use risk elements, etc.). This is sometimes referred to as “user acceptance
 715 testing (UAT).”
- 716 • Confirmation of acceptable failure behavior (‘fail safe’) in the clinical environment should be
 717 established.
- 718 • Consideration of the socio-technical⁹, technology, system environment¹⁰ (sometimes referred
 719 to as acceptance/installation testing) should be taken.
 720

721 ***Technology and Systems Environment Considerations***

- 722 • The extent of test coverage as driven by the risk profile of the device as determined by the
 723 intended use and SaMD definition statement¹¹ should be defined and exercised.
- 724 • Interoperability of components and compatibility to other platforms/devices/interfaces, etc.
 725 with which SaMD works should be considered.
- 726 • Provide adequate coverage and traceability to the known risk related functions of SaMD.
- 727 • Include the coverage of boundary conditions and exceptions (robustness, stress testing data
 728 security, integrity and continuity of SaMD availability).
- 729 • Employ rigorous impact analysis of changes made to SaMD (i.e., regression testing) to ensure
 730 updates do not compromise the safety, effectiveness and performance of SaMD.
 731

732 *Example: For both ACME and J&M, it is useful to construct test cases that allow a team to first*
 733 *test that the product functions as originally envisaged in the requirements. But, in the case of*

⁹ Socio-technical systems are systems that include technical systems but also operational processes and people who use and interact with the technical system. Socio-technical systems are governed by organizational policies and rules.

¹⁰ IMDRF SaMD WG N12 / Software as a Medical Device: Possible Framework for Risk Categorization and Corresponding Considerations - Section 9.1 Socio-Technical Environment Considerations.

¹¹ IMDRF SaMD WG N12 / Software as a Medical Device: Possible Framework for Risk Categorization and Corresponding Considerations - Section 6: SaMD Definition Statement.

734 *SaMD, it's important to additionally follow up with both clinical user acceptance testing – that is,*
735 *does the product fulfill its clinically-intended and correct function, as well as human factors testing*
736 *– that is, can a pre-defined set of inputs be given to multiple users and can the same outcomes be*
737 *obtained to demonstrate that the product is reasonably usable by most patients? In the latter case,*
738 *it's often useful to video patients performing the tests to “see” where they get stuck, where they*
739 *get it right, etc.*

740 *The following references in ISO 13485:2003 are applicable to this section: 7.3.5, 7.3.6 and 7.4.3*

741

742 8.5 Deployment

743 Deployment activities include aspects of delivery, installation, setup, and configuration that
744 support a controlled and effective distribution of SaMD to the customer. As part of risk
745 management, any hazards identified to be mitigated through deployment activities should be
746 addressed in these activities. Some aspects of deployment activities may need to be performed
747 every time a SaMD is distributed to the user (for e.g., distributing an upgrade or fix as a result of
748 maintenance activity). In some cases, especially when SaMD is a large system or is part of a large
749 system, the deployment activities may depend on an extensive collaborative effort with the user
750 (which can include training the users) for an effective use of SaMD or the system.

751

752 *Patient Safety and Clinical Environment Considerations*

- 753 • Deploying SaMD into a clinical environment can require considerations of peripheral
754 components if it is intended to be part of a clinical IT network. Therefore, the deployment
755 process often requires the cooperation of hospital IT, integration engineers, clinical
756 engineers, hospital risk managers and others who are often not part of a typical deployment
757 of other products. This may result in the need to define this process clearly to the customer,
758 establishing platform and OS requirements as well as responsibility agreements.
- 759 • Deployment needs to consider the end user and end user environment(s) of SaMD. This
760 would be particularly true if used in the home. The deployment process needs to be tailored
761 to the user's abilities and background. Appropriate human factors engineering practices
762 can aid in understanding this aspect and would impact the user requirements capture
763 process.
- 764 • Where possible deployment activities should make clearly available (through user
765 documentation and training) to the users any limitations with SaMD (for e.g., limitation of
766 the algorithm, provenance of data used, assumptions made, etc.)
- 767 • There should be communication of relevant information to enable correct installation and
768 configuration of the SaMD for appropriate integration with clinical workflows. This can
769 include instructions on how to verify the appropriateness of the installation and update to
770 SaMD as well as any changes made to the system environment.

771

772

773 *Technology and Systems Environment Considerations*

- 774 • Deployment should also include the collection of the settings and the environment of each
 775 installation for configuration management. This information should be maintained
 776 throughout the life of SaMD at each installation.
- 777 • Deployment of SaMD when installed on specific platforms should be according to the
 778 intended use that was verified and validated.
- 779 • Processes should be in place to ensure the appropriate and correct version is delivered to
 780 the user.
- 781 • The process of deployment may need to consider integrity of the software to ensure that
 782 the software can be delivered in a secure and reliable manner. The choice of deployment
 783 method may aid in developing this process.
- 784 • Proper deployment methods and procedures are required to ensure repeatability of SaMD
 785 delivery, installation, setup, configuration, intended operation and maintenance. It is
 786 important to ensure that the computing environments and platforms are sufficient to
 787 support proper intended use of the SaMD product.
- 788 • Methods that confirm that the software is delivered consistently and comprehensively and
 789 that it is used in a defined environment are also important. Non-technical measures may
 790 have to be implemented as part of the software product package for deployment. Risk
 791 management should highlight dependencies of hazardous scenarios or mitigations on
 792 external factors resulting from the computing environment and platforms, the use context
 793 and the application processes.

794 *Note: non-technical measures typically are warning/confirmation dialogs, warning*
 795 *displays, usage notes and user training requirements.*

796

797 *Example: For Both ACME and J&M, when a SaMD is deployed on ‘the cloud’ or a mobile*
 798 *platform, it is critical to ensure integrity of the deployment process with an extended network of*
 799 *stakeholders. For instance, a SaMD application that is designed for use on a smart phone must*
 800 *be supported with proper processes and documentation that include parties such as the app stores*
 801 *(e.g., iTunes, Google-play, private app clouds, etc.) as well as third party hosting service providers,*
 802 *etc. Unlike the deployment of a gaming app, these extended deployment stakeholders should be*
 803 *qualified and integrated per the QMS requirements for outsourcing and third party supplier*
 804 *management.*

805 *The following references in ISO 13485:2003 are applicable to this section: 7.2.3, 7.5, 7.5.1.2.1,*
 806 *7.5.1.2.2 and 7.5.1.2.3¹²*

807 **8.6 Maintenance**

808 Maintenance includes activities and tasks to modify a previously deployed SaMD. These activities
 809 should preserve the integrity of the SaMD without introducing new safety, effectiveness and

¹² For software products, capabilities like performance, security and safety heavily depend on the computing environment and platforms put in place. The use context and the processes used with the software product will generally influence the above capabilities. Though at the time of deployment or runtime the SaMD organization may have little or no technical control over such factors, the SaMD organization's hazards or mitigations analysis should consider the socio, technical aspects of the intended use and the intended/foreseeable use context of the SaMD

810 performance risks. Maintenance activities can be adaptive, perfective, preventive and corrective
811 activities originating from SaMD lifecycle processes and activities including in-service monitoring,
812 customer feedback, in-house testing or other information, or changes to user requirements or
813 changes in the socio-technical environment. When these activities require a change to a previously
814 deployed SaMD, all SaMD lifecycle processes and SaMD lifecycle activities should be carried out
815 during the implementation of the change.

816
817 To effectively manage the maintenance activities and any resulting changes and their impact to
818 SaMD, a risk assessment should be performed to determine if the change(s) affect SaMD
819 categorization and the core functionality of SaMD as outlined in the SaMD definition statement.¹³
820

821 ***Patient Safety and Clinical Environment Considerations***

- 822 • Within the context of SaMD it is important to understand how systems, software, context
823 of use, usability, data, and documentation might be affected by changes, particularly with
824 regards to safety, effectiveness and performance;
- 825 • As highlighted in other SaMD lifecycle processes and SaMD lifecycle activities, people,
826 technology, and infrastructure and new risks resulting from implementation and use
827 activities should be considered.

828

829 ***Technology and Systems Environment Considerations***

- 830 • The manufacturer should be aware of any risk impact of changes to architecture and code;
- 831 • There should be processes to manage risk arising from changes to system, environment,
832 and data;

833

834 *Example: In SaMD that involves mobile software development, maintenance can include ensuring*
835 *that the SaMD product continues to operate as intended when operating system updates (such as*
836 *iOS, Android, Windows Mobile, etc.) are made. In the case of ACME, a maintenance organization*
837 *may have resources that are dedicated to watch, track and plan for any residual development or*
838 *testing required as the OS version changes. In the case of J&M, it may be an “all-hands-on-deck”*
839 *approach that ensures continuity and integrity of the SaMD product as the new OS version is*
840 *introduced.*

841

842 *The following references in ISO 13485:2003 are applicable to this section: 7.2.3, 7.5, 7.5.1.2.3,*
843 *7.5.4, and 8.2.1*

844

844 **8.7 Decommissioning (Retirement or End-of-Life activity)**

845 The purpose of decommissioning activities is to terminate maintenance, support and distribution
846 of SaMD in a controlled and a managed fashion. These activities are important to minimize the
847 public health impact as a result of retiring the SaMD. These activities may include, aspects of
848 configuration management that apply to the document, source code or the delivered SaMD and
849 communicating a plan to the user for gracefully terminating maintenance and support of SaMD.

850

¹³ IMDRF SaMD WG N12 / Software as a Medical Device: Possible Framework for Risk Categorization and Corresponding Considerations - Section 8.2 Changes

851 The process signals an end to active support, and may entail deactivation and/or removal of
852 SaMD and its supporting data. The decommissioning of SaMD data is of special importance,
853 since while the product and/or access may terminate, certain legislations may dictate that the data
854 must be appropriately archived, and not destroyed.
855

856 ***Patient Safety and Clinical Environment Considerations***

- 857 • Provide clarity to users that no bug fixes, updates, patches or technical support will be
858 available once end-of-life (EOL) is signed-off.
- 859 • Appropriately safeguard patient data and any other confidential data. This may include
860 removal, migrating patients to a new SaMD or other product, safe archival of user
861 information, etc.
862

863 ***Technology and Systems Environment Considerations***

- 864 • Inform customers of important EOL milestones, with sufficient lead-time for users to
865 find, evaluate and qualify possible alternatives.
- 866 • Archive a user's environment in an agreed-upon state, which may include steps to protect
867 the security and integrity of information and/or systems.
- 868 • Officially document, per QMS guidelines, that the SaMD has been decommissioned.
869

870 *Example: Medical data may be requested years after the product or its use has been*
871 *decommissioned. For both ACME and J&M, it is necessary to have effective procedures that*
872 *ensure effective decommissioning, documentation and data archival for SaMD products.*

873 *The following references in ISO 13485:2003 are applicable to this section: 4.2 and 7.*

IMDRF/SaMD WG (PD1)/N23R3

874 **Appendix A - ISO 13485:2003 references**

IMDRF/SaMD WG/N23 WD1 (Section)	ISO 13485:2003 (Clause)
5.0--SaMD Quality Management Principles	4 Quality Management System 5 Management Responsibility
6.0--SaMD Governance: Leadership And Organizational Support	--
6.1--Leadership And Accountability In The Organization	5 Management Responsibility 5.1 Management Commitment 5.2 Customer Focus 5.3 Quality Policy 5.4 Planning 5.5 Responsibility, Authority and Communication 5.6 Management Review 8.2.2 Internal Audit
6.2--Resource And Infrastructure Management	6 Resource Management
6.2.1--People	6.1 Provision of Resources 6.2 Human Resources
6.2.2--Infrastructure And Work Environment	6.3 Infrastructure 6.4 Work Environment
7.0--Managing SaMD Lifecycle Processes	--
7.1--Product Planning	5.4 Planning 7.1 Planning of Product Realization 7.3.1 Design and Development Planning
7.2--Risk Management: A Patient Safety Focused Process	7.1 Planning of Product Realization
7.3--Document Control And Records	4.2 Documentation Requirements
7.4--Configuration Management And Control	4.2.3 Control of Documents 4.2.4 Control of Records 7.3.7 Control of Design and Development Changes 7.5.1 Control of Production and Service Provisions 7.5.3 Identification and Traceability
7.5--Measurement, Analysis And Improvement Of Processes And Product	7.2.3 Customer Communication 8.1 Measurement, Analysis and Improvement - General 8.2 Monitoring and Measurement 8.3 Control of Nonconforming Product 8.4 Analysis of Data 8.5 Improvement
7.6--Managing Outsourced Processes And Products	7.4 Purchasing 7.4.1 Purchasing Process 7.4.2 Purchasing Information 8.5.1 Improvement

IMDRF/SaMD WG (PD1)/N23R3

IMDRF/SaMD WG/N23 WD1 (Section)	ISO 13485:2003 (Clause)
8.0--SaMD Lifecycle Activities	7.0 Product Realization
8.1--Requirements	7.2.1 Determination of Requirements Related to the Product 7.2.2 Review of Requirements Related to the Product 4.2 Documentation requirements 7.1d Records Needed to Provide Evidence That the Realization Processes and Resulting Product Meet Requirements
8.2--Design + 8.3--Development	7.3 Design and Development 7.3.2 Design and Development Inputs 7.3.3 Design and development Outputs 7.3.4 Design and Development Review 7.3.7 Control of Design and Development Changes
8.4--Verification And Validation	7.3.5 Design and Development verification 7.3.6 Design and Development validation 7.4.3 Verification of Purchased Product
8.5--Deployment	7.2.3 Customer Communication 7.5 Production and Service Provision 7.5.1.2.1 Cleanliness of Product and Contamination Control (<i>as it relates to cybersecurity</i>) 7.5.1.2.2 Installation Activities 7.5.1.2.3 Servicing Activities
8.6--Maintenance	7.2.3 Customer Communication 7.5 Production and Service Provision 7.5.1.2.3 Servicing Activities 7.5.4 Customer Property (<i>as it relates to intellectual property and confidential health information</i>) 8.2.1 Feedback
8.7--Decommissioning	4.2 Documentation Requirements 7 Product Realization

875

IMDRF/SaMD WG/N23 WD1 (Section)	ISO 13485:2003 (Clause)
These clauses from ISO 13485:2003 are not applicable for SaMD.	7.5.3.2.2 Particular Requirements for Active Implantable Medical Devices and Implantable Medical Devices 7.5.5 Preservation of product 7.6 Control of Monitoring and Measuring Devices 8.2.4.2 Particular requirements for active implantable medical devices

876